Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Akeso Inc.
Sirius has joined the race to develop China’s first homegrown RNAi therapy and is backing its assets’ potential in chronic cardiovascular disorders, including possible once-yearly dosing, the venture’s CEO tells Scrip in an interview.
CDER missed six goal dates among its 2023 novel approvals, reflecting safety concerns as well as pandemic-related inspection delays; Duchenne muscular dystrophy accelerated approval disagreements caused the biologics center’s lone missed goal.
The emergence of China from API manufacturer to an innovation leader, fuelled by domestic investments and home-grown talent, has been one of the most remarkable trends of the last decade.
Chinese firm Hasten has gained greater China rights to LIB Therapeutics’ lerodalcibep for hypercholesterolemia and believes its bet on the unique PCSK9-binding small protein will be backed by strong commercialization capability, the company says in an interview with Scrip.
- Large Molecule
- Other Names / Subsidiaries
- Akesobio Australia Pty Ltd
- Akeso Biopharma, Inc.
- Kangfang Biotechnology
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.